Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Agilent TechnologiesMIL:1A 70 EBIT per Share is €5.07 as of Apr. 2026. GuruFocus rates MIL:1A with a GF Score™ of 70/100 and a GF Value™ of €123.95 (Fairly Valued). The stock has 1 warning sign investors should review. Among 166 Medical Diagnostics & Research companies, Agilent Technologies ranks worse than 66.87% on this metric.
Agilent Technologies's EBIT per Share for the
three
months ended in Apr. 2026 was €1.31.
Its EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2026 was €5.07.
During the past 12 months, the average EBIT per Share Growth Rate of Agilent Technologies was 10.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -1.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 10.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 13.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Agilent Technologies's EBIT per Share or its related term are showing as below:
MIL:1A'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -49.4 Med: 16.4 Max: 185.7
Current: -1.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Agilent Technologies was 185.70% per year. The lowest was -49.40% per year. And the median was 16.40% per year.
MIL:1A's 3-Year EBIT Growth Rate is ranked worse than 66.87% of 166
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs MIL:1A: -1.30
Agilent Technologies (MIL:1A) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Agilent Technologies EBIT per Share Related Terms
Agilent Technologies EBIT per Share Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (MIL:1A) has a EBIT per Share of €5.07 as of Apr. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Agilent Technologies and its competitors. According to the industry distribution chart, Agilent Technologies ranks #111 out of 166 companies in the Medical Diagnostics & Research industry, placing it in the top 66.9%.
Is Agilent Technologies' EBIT per Share too high?
Agilent Technologies' current EBIT per Share is €5.07. Based on the distribution chart, Agilent Technologies ranks #111 out of 166 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Agilent Technologies has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' EBIT per Share compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #111 out of 166 companies for EBIT per Share. This places Agilent Technologies in the lower half of its industry. The industry median EBIT per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 166 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Agilent Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agilent Technologies's current EBIT per Share is €5.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (MIL:1A) is currently considered Fairly Valued. The stock's GF Value™ is €123.95, compared to a current price of €117.45 — trading 5.2% below its estimated fair value. The current EBIT per Share is €5.07. Agilent Technologies' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Agilent Technologies (MIL:1A), the current EBIT per Share is €5.07 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (MIL:1A) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €117.45 is trading 5.2% below its estimated GF Value™ of €123.95.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for MIL:1A:
EBIT per Share: €5.07
GF Value™: €123.95 vs. price of €117.45 (5.2% below fair value)
No single metric tells the full story. See the MIL:1A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
70GF Score
Get the complete analysis for MIL:1A
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1A has been successfully added to your 
